LENZ — Lenz Therapeutics Share Price
Last trade - 00:00- $740.08m
- $531.05m
- 31
- 25
- 66
- 35
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.63 | ||
| Price to Tang. Book | 3.63 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -28.6% | ||
| Return on Equity | -25.68% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 7.63 | 49.19 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
Directors
- Perry Karsen NEC (66)
- Joshua Lehrer-Graiwer PRE (47)
- Philip Gutry DIR (47)
- Abraham Bassan IND (36)
- Jerel Davis IND (44)
- Kristen Hege IND (58)
- Joseph Jimenez IND (61)
- Carlo Rizzuto IND (51)
- Smital Shah IND (45)
- Joanne Viney IND (55)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 29th, 2019
- Public Since
- June 25th, 2021
- No. of Shareholders
- 53
- No. of Employees
- 42
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 27,543,120
- Address
- 201 Lomas Santa Fe Drive, Suite 300, SOLANA BEACH, 92075
- Web
- https://lenz-tx.com/
- Phone
- +1 8589257000
- Auditors
- Ernst & Young LLP
Upcoming Events for LENZ
Similar to LENZ
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
As of Today at 21:44 UTC, shares in Lenz Therapeutics are trading at $26.87. This share price information is delayed by 15 minutes.
Shares in Lenz Therapeutics last closed at $26.87 and the price had moved by +73.92% over the past 365 days. In terms of relative price strength the Lenz Therapeutics share price has outperformed the S&P500 Index by +60.53% over the past year.
The overall consensus recommendation for Lenz Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreLenz Therapeutics does not currently pay a dividend.
Lenz Therapeutics does not currently pay a dividend.
Lenz Therapeutics does not currently pay a dividend.
To buy shares in Lenz Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $26.87, shares in Lenz Therapeutics had a market capitalisation of $740.08m.
Here are the trading details for Lenz Therapeutics:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: LENZ
Based on an overall assessment of its quality, value and momentum Lenz Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Lenz Therapeutics is $44.14. That is 64.27% above the last closing price of $26.87.
Analysts covering Lenz Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$3.00 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lenz Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +4.81%.
As of the last closing price of $26.87, shares in Lenz Therapeutics were trading +4.14% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Lenz Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $26.87.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Lenz Therapeutics' management team is headed by:
- Perry Karsen - NEC
- Joshua Lehrer-Graiwer - PRE
- Philip Gutry - DIR
- Abraham Bassan - IND
- Jerel Davis - IND
- Kristen Hege - IND
- Joseph Jimenez - IND
- Carlo Rizzuto - IND
- Smital Shah - IND
- Joanne Viney - IND